Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:39:07.155Z.
Calculation as of: 2026-10-06T22:39:07.155Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc4657557541446f84d9f7820ae4f915e84790dbce56ed6e08d87a0074ca8553
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$3.38B
EV/EBITDA Ratio
31.19x
TTM Avg
29.77x
3Y Avg
69.20x
5Y Avg
69.20x
Market Cap
$3.19B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.12B
EV/EBITDA Ratio
N/A
TTM Avg
9.21x
3Y Avg
9.21x
5Y Avg
9.21x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | $3.31B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.30B | 189.34x | 115.31x | 72.49x | 72.49x |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 31.19x | 29.77x | 69.20x | 69.20x |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | N/A | N/A | N/A | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | N/A | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A | N/A | N/A | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A | 9.21x | 9.21x | 9.21x |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | 286.35x | 665.65x | 665.65x | 665.65x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
